18 F-FDG pet interim and determination of cellular origin by immunohistochemistry identify a group of very good prognosis in patients with diffuse large B cell lymphoma in the rituximab era (2014)
- Authors:
- Autor USP: PEREIRA, JULIANA - FM
- Unidade: FM
- Subjects: LINFOMA (ETIOLOGIA); FÁRMACOS IMUNOSSUPRESSORES; IMUNOHISTOQUÍMICA; PROGNÓSTICO
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Blood
- Volume/Número/Paginação/Ano: v. 124, n. 21, res. 3051, suppl, 2014
- Conference titles: Annual Meeting and Exposition / ASH
-
ABNT
LAGE, Luis Alberto de P. Covas et al. 18 F-FDG pet interim and determination of cellular origin by immunohistochemistry identify a group of very good prognosis in patients with diffuse large B cell lymphoma in the rituximab era. Blood. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://ash.confex.com/ash/2014/webprogram/Paper69673.html. Acesso em: 24 abr. 2024. , 2014 -
APA
Lage, L. A. de P. C., Hallack Neto, A. E., Santucci, R., Costa, R. O., Siqueira, S., Paula, H. M. de, & Pereira, J. (2014). 18 F-FDG pet interim and determination of cellular origin by immunohistochemistry identify a group of very good prognosis in patients with diffuse large B cell lymphoma in the rituximab era. Blood. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de https://ash.confex.com/ash/2014/webprogram/Paper69673.html -
NLM
Lage LA de PC, Hallack Neto AE, Santucci R, Costa RO, Siqueira S, Paula HM de, Pereira J. 18 F-FDG pet interim and determination of cellular origin by immunohistochemistry identify a group of very good prognosis in patients with diffuse large B cell lymphoma in the rituximab era [Internet]. Blood. 2014 ; 124( 21):[citado 2024 abr. 24 ] Available from: https://ash.confex.com/ash/2014/webprogram/Paper69673.html -
Vancouver
Lage LA de PC, Hallack Neto AE, Santucci R, Costa RO, Siqueira S, Paula HM de, Pereira J. 18 F-FDG pet interim and determination of cellular origin by immunohistochemistry identify a group of very good prognosis in patients with diffuse large B cell lymphoma in the rituximab era [Internet]. Blood. 2014 ; 124( 21):[citado 2024 abr. 24 ] Available from: https://ash.confex.com/ash/2014/webprogram/Paper69673.html - CD4+ lymphocytes in asymptomatic HTLV-1 carriers present cell cycle arrest in GO/G1 phase
- Expression of CysLTR1 and 2 in Maturating Lymphocytes of Hyperplasic Tonsils Compared to Peripheral Cells in Children
- Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: relation to hemodynamic parameters and the presence of Down syndrome
- Time-to-treatment of diffuse large B-cell lymphoma in São Paulo
- Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study
- Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances
- Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma
- Comparison between R-CHOP vs R-CHOP plus etoposide in untreated patients with primary mediastinal B-cell lymphoma: Preliminary findings
- Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*)
- Follicular lymphoma: refining prognostic models and impact of pod-24 in clinical outcomes
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
